GLP1R and type 2 diabetes mellitus: Similarly, the glucagon-like peptide-1 receptor agonist (GLP1-RA), semaglutide, has been associated with reduced PCATa in patients with T2DM, suggesting that semaglutide possesses anti-inflammatory properties that may modulate coronary inflammation [31].